560 related articles for article (PubMed ID: 27506761)
21. Challenges in Alzheimer's Disease Diagnostic Work-Up: Amyloid Biomarker Incongruences.
Lombardi G; Pupi A; Bessi V; Polito C; Padiglioni S; Ferrari C; Lucidi G; Berti V; De Cristofaro MT; Piaceri I; Bagnoli S; Nacmias B; Sorbi S
J Alzheimers Dis; 2020; 77(1):203-217. PubMed ID: 32716357
[TBL] [Abstract][Full Text] [Related]
22. Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimer's Disease Pathology Between Three Independent Assay Platforms.
Doecke JD; Rembach A; Villemagne VL; Varghese S; Rainey-Smith S; Sarros S; Evered LA; Fowler CJ; Pertile KK; Rumble RL; Trounson B; Taddei K; Laws SM; Macaulay SL; Bush AI; Ellis KA; Martins R; Ames D; Silbert B; Vanderstichele H; Masters CL; Darby DG; Li QX; Collins S;
J Alzheimers Dis; 2018; 61(1):169-183. PubMed ID: 29171991
[TBL] [Abstract][Full Text] [Related]
23. What are the Most Frequently Impaired Markers of Neurodegeneration in ADNI Subjects?
Andriuta D; Moullart V; Schraen S; Devendeville A; Meyer ME; Godefroy O;
J Alzheimers Dis; 2016; 51(3):793-800. PubMed ID: 26923012
[TBL] [Abstract][Full Text] [Related]
24. Enrichment through biomarkers in clinical trials of Alzheimer's drugs in patients with mild cognitive impairment.
Lorenzi M; Donohue M; Paternicò D; Scarpazza C; Ostrowitzki S; Blin O; Irving E; Frisoni GB;
Neurobiol Aging; 2010 Aug; 31(8):1443-51, 1451.e1. PubMed ID: 20541287
[TBL] [Abstract][Full Text] [Related]
25. Florbetapir positron emission tomography and cerebrospinal fluid biomarkers.
Hake A; Trzepacz PT; Wang S; Yu P; Case M; Hochstetler H; Witte MM; Degenhardt EK; Dean RA;
Alzheimers Dement; 2015 Aug; 11(8):986-93. PubMed ID: 25916563
[TBL] [Abstract][Full Text] [Related]
26. MRI and CSF studies in the early diagnosis of Alzheimer's disease.
de Leon MJ; DeSanti S; Zinkowski R; Mehta PD; Pratico D; Segal S; Clark C; Kerkman D; DeBernardis J; Li J; Lair L; Reisberg B; Tsui W; Rusinek H
J Intern Med; 2004 Sep; 256(3):205-23. PubMed ID: 15324364
[TBL] [Abstract][Full Text] [Related]
27. Clinic-Based Validation of Cerebrospinal Fluid Biomarkers with Florbetapir PET for Diagnosis of Dementia.
Álvarez I; Aguilar M; González JM; Ysamat M; Lorenzo-Bosquet C; Alonso A; Tartari JP; Romero S; Diez-Fairen M; Carcel M; Pujalte F; Pastor P
J Alzheimers Dis; 2018; 61(1):135-143. PubMed ID: 29154286
[TBL] [Abstract][Full Text] [Related]
28. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
[TBL] [Abstract][Full Text] [Related]
29. Why Is Amyloid-β PET Requested After Performing CSF Biomarkers?
Reimand J; Groot C; Teunissen CE; Windhorst AD; Boellaard R; Barkhof F; Nazarenko S; van der Flier WM; van Berckel BNM; Scheltens P; Ossenkoppele R; Bouwman F
J Alzheimers Dis; 2020; 73(2):559-569. PubMed ID: 31796674
[TBL] [Abstract][Full Text] [Related]
30. Spatially distinct atrophy is linked to β-amyloid and tau in preclinical Alzheimer disease.
Wang L; Benzinger TL; Hassenstab J; Blazey T; Owen C; Liu J; Fagan AM; Morris JC; Ances BM
Neurology; 2015 Mar; 84(12):1254-60. PubMed ID: 25716355
[TBL] [Abstract][Full Text] [Related]
31. The use of biomarkers for the etiologic diagnosis of MCI in Europe: an EADC survey.
Bocchetta M; Galluzzi S; Kehoe PG; Aguera E; Bernabei R; Bullock R; Ceccaldi M; Dartigues JF; de Mendonça A; Didic M; Eriksdotter M; Félician O; Frölich L; Gertz HJ; Hallikainen M; Hasselbalch SG; Hausner L; Heuser I; Jessen F; Jones RW; Kurz A; Lawlor B; Lleo A; Martinez-Lage P; Mecocci P; Mehrabian S; Monsch A; Nobili F; Nordberg A; Rikkert MO; Orgogozo JM; Pasquier F; Peters O; Salmon E; Sánchez-Castellano C; Santana I; Sarazin M; Traykov L; Tsolaki M; Visser PJ; Wallin ÅK; Wilcock G; Wilkinson D; Wolf H; Yener G; Zekry D; Frisoni GB
Alzheimers Dement; 2015 Feb; 11(2):195-206.e1. PubMed ID: 25150733
[TBL] [Abstract][Full Text] [Related]
32. Hypometabolism and altered cerebrospinal fluid markers in normal apolipoprotein E E4 carriers with subjective memory complaints.
Mosconi L; De Santi S; Brys M; Tsui WH; Pirraglia E; Glodzik-Sobanska L; Rich KE; Switalski R; Mehta PD; Pratico D; Zinkowski R; Blennow K; de Leon MJ
Biol Psychiatry; 2008 Mar; 63(6):609-18. PubMed ID: 17720148
[TBL] [Abstract][Full Text] [Related]
33. Dementia mimicking Alzheimer's disease Owing to a tau mutation: CSF and PET findings.
Tolboom N; Koedam EL; Schott JM; Yaqub M; Blankenstein MA; Barkhof F; Pijnenburg YA; Lammertsma AA; Scheltens P; van Berckel BN
Alzheimer Dis Assoc Disord; 2010; 24(3):303-7. PubMed ID: 20683187
[TBL] [Abstract][Full Text] [Related]
34. Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease.
Tarawneh R; Head D; Allison S; Buckles V; Fagan AM; Ladenson JH; Morris JC; Holtzman DM
JAMA Neurol; 2015 Jun; 72(6):656-65. PubMed ID: 25867677
[TBL] [Abstract][Full Text] [Related]
35. Concordance between brain
Rubí S; Noguera A; Tarongí S; Oporto M; García A; Vico H; Espino A; Picado MJ; Mas A; Peña C; Amer G
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(1):3-8. PubMed ID: 28645685
[TBL] [Abstract][Full Text] [Related]
36. Value of neuropsychological tests, neuroimaging, and biomarkers for diagnosing Alzheimer's disease in younger and older age cohorts.
Schmand B; Eikelenboom P; van Gool WA;
J Am Geriatr Soc; 2011 Sep; 59(9):1705-10. PubMed ID: 21883100
[TBL] [Abstract][Full Text] [Related]
37. Alzheimer's Disease Cerebrospinal Fluid and Neuroimaging Biomarkers: Diagnostic Accuracy and Relationship to Drug Efficacy.
Khan TK; Alkon DL
J Alzheimers Dis; 2015; 46(4):817-36. PubMed ID: 26402622
[TBL] [Abstract][Full Text] [Related]
38. Comparison between clinical diagnosis and CSF biomarkers of Alzheimer disease in elderly patients with late onset psychosis: Helsinki Old Age Psychosis Study (HOPS).
Seppälä TT; Louhija UM; Appelberg B; Herukka SK; Juva K
Am J Geriatr Psychiatry; 2014 Sep; 22(9):908-16. PubMed ID: 23597931
[TBL] [Abstract][Full Text] [Related]
39. The application of cerebrospinal fluid biomarkers in early diagnosis of Alzheimer disease.
Blennow K; Zetterberg H
Med Clin North Am; 2013 May; 97(3):369-76. PubMed ID: 23642576
[TBL] [Abstract][Full Text] [Related]
40. Additional use of Aβ₄₂/Aβ₄₀ ratio with cerebrospinal fluid biomarkers P-tau and Aβ₄₂ increases the level of evidence of Alzheimer's disease pathophysiological process in routine practice.
Sauvée M; DidierLaurent G; Latarche C; Escanyé MC; Olivier JL; Malaplate-Armand C
J Alzheimers Dis; 2014; 41(2):377-86. PubMed ID: 24614902
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]